TEQCool introduces a new unique cooling method
It has been known for long that a lower body temperature limits neurological damage caused by hypoxia in cardiac arrest, improves the clinical outcome and the quality of life for those who survive cardiac arrest.
The world’s largest scientific study to date in mild hypothermia, the so-called TTM2 (Target Temperature Management) study, involving 1,900 cardiac arrest patients was published on June 17, 2021, in the New England Journal of Medicine (Nielsen et al, 2021))
In summary, the TTM2 study shows that the survival rate is equivalent, and that the clinical outcome after 6 months is equivalent, between the hypothermia group, which was cooled to a body temperature of 33°C, and the normothermia group where the cold treatment was started only when the patient reached a fever level of ≥37.8°C (46% of the patients in the normothermia group were cooled in the TTM2 study).
TEQCool’s cooling solution is an effective aid that is specially adapted to maintain normothermia and prevent fever in cardiac arrest patients by circulating fluid in balloon catheters in the cardiac arrest patient’s nasal cavities.
Temperature control is an active treatment to achieve and maintain a patient’s specific body temperature during a specific period of time, in order to improve health outcomes.
Do you wish to learn more about our unique cooling system? Contact us today!